STAMFORD, Conn., May 14 /PRNewswire/ -- Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp. (Nasdaq: SPDE), today announced that its Zargis Cardioscan device and the compatible 3M™ Littmann® Electronic Stethoscope Model 3200 were the joint recipients of a Gold Award on April 29th at The Edison Best New Products Award gala, presented by Discovery Channel in New York City. The prestigious Gold Award is the top honor given by the Edison Award Steering Committee for product excellence in innovation, creativity and ingenuity, as demonstrated by inventor Thomas Alva Edison. Zargis and 3M were recognized in the Electronics and Computers category—the category in which the Apple® iPhone was the 2009 Gold Award winner.
Zargis Cardioscan software supports physicians in analyzing cardiac sounds for the identification and classification of suspected murmurs, which can be signs of heart disease, and allows healthcare professionals to record, visualize and transmit recordings made with a stethoscope. The software represents a breakthrough in computer-aided auscultation that has the potential to reduce unnecessary referrals.
"Pairing the Littmann Electronic Stethoscope Model 3200 with Zargis Cardioscan software is a huge advancement in changing the way clinicians listen to and interpret heart sounds," said Debra Rectenwald, president and general manager, 3M Infection Prevention Division.
About Zargis Medical Corp.
Zargis is a global medical device company focused on improving health outcomes and cost-effectiveness through diagnostic support software and innovation. Zargis is majority-owned by Speedus Corp. (Nasdaq: SPDE), and both 3M Company and Siemens Corporate Research, a division of Siemens AG (NYSE: SI), hold equity positions.
Statements contained herein that are not historical facts, including but not limited to statements about the Company's product, corporate identity and focus, may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company, including, but not limited to, the continuing development of the Company's sales, marketing and support efforts.
|SOURCE Speedus Corp.|
Copyright©2010 PR Newswire.
All rights reserved